Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients

NCT04529278 on ClinicalTrials.gov · last registry update 2023-04-14

A small phase 2 — 18 participants, against a typical 110. The sponsor logged completion for 17 January 2023. Primary outcome, as filed: Weight Loss at Week 26. liraglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: UNKNOWN
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Fondation Hôpital Saint-Joseph
Sponsor type: Other
Enrollment: 18
Started: 2021-01-18
Primary completion: 2023-01-17 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Weight Loss at Week 26

Conditions studied

Diabetes Mellitus, Type 2 · Hemodialysis · Obese

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.